2013 Formulas for Verification of Foreign Patented Drug Prices

France

  • FP given in Vidal in euros
  • FP (reported in the formulary under column “Px–Achat”) is directly comparable to the PP reported by the patentee
  • The WP is derived as follows:
If: FP ≤ 22.90 WP = FP/1.0993
22.90 < FP ≤ 150.00 WP = 20.83 + (FP − 22.90)/1.06
FP > 150.00 WP = 140.73 + (FP − 150)/1.02
  • No price comparable to the HP reported by the patentee

Germany

  • FP given in Rote Liste in euros
  • FP includes 19% VAT; FPN = FP/1.19
  • PP = (FPN − 8.10)/1.03
  • The WP is derived as follows:

WP = (PP − 0.70)/1.0315

  • No price comparable to the HP reported by the patentee

Italy

  • FP given in l&'Informatore Farmaceutico in euros
  • FP includes a 10% VAT; FPN = FP/1.10
  • PP = FPN x 0.733
  • WP = FPN x 0.6665
  • No price comparable to the HP reported by patentee

Sweden

  • FP given on TLV website in Swedish kronas

Brand Drugs

  • The PP is derived as follows:
If: FP ≤ 121.25 PP = (FP − 31.25)/1.20
121.25 < FP ≤ 353.0 PP = (FP − 44.00)/1.03
353.0 < FP ≤ 6,117.0 PP = (FP − 47.00)/1.02
FP > 6,117.0 PP = FP − 167.0
  • The WP is derived as follows:
If: FP ≤ 121.25 WP = (FP − 31.25)/(1.20 x 1.032)
121.25 < FP ≤ 353.00 WP = (FP − 44.00)/(1.03 x 1.032)
353.0 < FP ≤ 6,117.0 WP = (FP − 47.00)/(1.02 x 1.032)
FP > 6,117.0 WP = (FP − 167.0)/1.032
  • No price comparable to the HP reported by the patentee

Generic Substitution

  • The PP is derived as follows:
If: FP ≤ 131.25 PP = [FP − (31.25 + 10.00)]/1.20
131.25 < FP ≤ 363.0 PP = [FP − (44.00 + 10.00)]/1.03
363.0 < FP ≤ 6,117.0 PP = [FP − (47.00 + 10.00)]/1.02
FP > 6,117.0 PP = FP − (167.0 + 10.00)
  • The WP is derived as follows:
If: FP ≤ 131.25 WP = [FP − (31.25 + 10.00)]/(1.20 x 1.032)
131.25 < FP ≤ 363.00 WP = [FP − (44.00 + 10.00)]/(1.03 x 1.032)
363.0 < FP ≤ 6,117.0 WP = [FP − (47.00 + 10.00)]/(1.02 x 1.032)
FP > 6,117.0 WP = [FP − (167.0 + 10.00)]/1.032
  • No price comparable to the HP reported by patentee

Switzerland

  • FP given on BAG website in Swiss francs
  • FP is directly comparable to the WP reported by the patentee
  • No prices comparable to the HP and the PP reported by patentee

United Kingdom

  • FP given in the Monthly Index of Medical Specialties (MIMS) in UK pounds
  • FP is directly comparable to the PP reported by the patentee
  • No prices comparable to the HP and the WP reported by patentee

United States

  • No regulated mark–ups
  • Prices given in US dollars
  • The Direct Price is directly comparable to the HP, PP and/or WP reported by the patentee
  • The Wholesale Acquisition Cost (WAC) price is directly comparable to the WP reported by the patentee
  • The Federal Supply Schedule (FSS) price has been required by the PMPRB since 1998 and included in IPC tests since 2000
Date modified: